Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Calcium Supplementation Could Lower Hip Fracture Costs $2.6 Bil. -Study

This article was originally published in The Tan Sheet

Executive Summary

Annual medical expenses from hip fractures would drop $2.6 bil. if people 50 and older took 1,200 mg-1,500 mg of supplemental calcium per day, SmithKline New Product Research Associate Director Adrianne Bendich, PhD, et al., report in a study entitled "Supplemental Calcium for the Prevention of Hip Fracture: Potential Health-Economic Benefits." The study appears in the June issue of Clinical Therapeutics.

You may also be interested in...



Tums Print Ads Play Up PMS Relief Angle Indicated In Recent Study

SmithKline Beecham print advertising for Tums antacids is emphasizing the calcium supplement's role in reducing the severity of premenstrual syndrome as indicated in a large-scale clinical published in the August issue of the Journal of Obstetrics and Gynecology.

P&G Billing Metamucil As Dual OTC/"Heart Healthy" Dietary Supplement

Procter & Gamble is changing the labeling for its psyllium-based fiber laxative Metamucil to a "dual" OTC drug and dietary fiber supplement, the firm announced Nov. 6.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel